Article

Exploring the Binding Efficacy of Ivermectin Against the Key Proteins of SARS-CoV-2 Pathogenesis: an in silico Approach

2021-03-25

Abstract excerpt

Aim: COVID-19 is currently the biggest threat to mankind. Recently, ivermectin (a US FDA-approved antiparasitic drug) has been explored as an anti-SARS-CoV-2 agent. Herein, we have studied the possible mechanism of action of ivermectin using in silico approaches. Materials & methods: Interaction of ivermectin against the key proteins involved in SARS-CoV-2 pathogenesis were investigated through molecular docking a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: fa5aa4f4-a4e0-55ae-8ad4-e7475887a2be
DOI: 10.2217/fvl-2020-0342

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Exploring the Binding Efficacy of Ivermectin Against the Key Proteins of SARS-CoV-2 Pathogenesis: an in silico ApproachDOI 10.2217/fvl-2020-0342Read

Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2Semantic proximity Read

Prospective mode of action of Ivermectin: SARS-CoV-2Semantic proximity Read

Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replicationSemantic proximity Read

THE THERAPEUTIC POTENTIAL OF IVERMECTIN FOR COVID-19: A SYSTEMATIC REVIEW OF MECHANISMS AND EVIDENCESemantic proximity Read

Interaction of Drug Candidates with Various SARS-CoV‑2 Receptors: An in Silico Study to Combat COVID-19Semantic proximity Read

THE THERAPEUTIC POTENTIAL OF IVERMECTIN FOR COVID-19: A SYSTEMATIC REVIEW OF MECHANISMS AND EVIDENCESemantic proximity Read

Research Into Potential Therapies Against COVID-19, With Focus On IvermectinSemantic proximity Read

Research Into Potential Therapies Against COVID-19, With Focus On IvermectinSemantic proximity Read

In Silico Evaluation of Ten Monoclonal Antibodies Neutralization Power of SARS-CoV-2 Variants EG.5, BA.2.86 and JN.1Semantic proximity Read

In silico evaluation of ten monoclonal antibodies neutralization power of SARS-CoV-2 variants EG.5, BA.2.86 and JN.1Semantic proximity Read

Evaluation of the Effectiveness and Safety of Adding Ivermectin to Treatment in Severe COVID-19 PatientsSemantic proximity Read

Integrated Docking and Enhanced Sampling Based Selection of Repurposing Drugs for SARS-CoV-2 by Targeting Host Dependent FactorsSemantic proximity Read